S&P 500   2,984.83 (-0.44%)
DOW   26,887.10 (-0.51%)
QQQ   191.49 (-0.99%)
AAPL   235.39 (+0.45%)
MSFT   137.33 (-1.54%)
GOOGL   1,244.85 (-0.72%)
AMZN   1,761.89 (-1.59%)
CGC   19.89 (-2.07%)
MU   43.50 (-4.27%)
BABA   170.70 (-3.14%)
GE   9.00 (-0.66%)
AMD   30.59 (-1.39%)
F   9.24 (+1.54%)
ACB   3.70 (-2.63%)
NFLX   275.89 (-5.95%)
GILD   64.60 (-0.86%)
DIS   131.34 (-1.15%)
S&P 500   2,984.83 (-0.44%)
DOW   26,887.10 (-0.51%)
QQQ   191.49 (-0.99%)
AAPL   235.39 (+0.45%)
MSFT   137.33 (-1.54%)
GOOGL   1,244.85 (-0.72%)
AMZN   1,761.89 (-1.59%)
CGC   19.89 (-2.07%)
MU   43.50 (-4.27%)
BABA   170.70 (-3.14%)
GE   9.00 (-0.66%)
AMD   30.59 (-1.39%)
F   9.24 (+1.54%)
ACB   3.70 (-2.63%)
NFLX   275.89 (-5.95%)
GILD   64.60 (-0.86%)
DIS   131.34 (-1.15%)
Log in

Depomed Stock Price, News & Analysis (NYSE:ASRT)

$1.18
-0.07 (-5.60 %)
(As of 10/18/2019 12:14 PM ET)
Today's Range
$1.17
Now: $1.18
$1.24
50-Day Range
$1.04
MA: $1.30
$1.47
52-Week Range
$1.01
Now: $1.18
$6.07
Volume15,267 shs
Average Volume1.01 million shs
Market Capitalization$76.49 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Assertio Therapeutics, Inc., a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; and Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults. The company also provides NUCYNTA ER (tapentadol extended release tablet), a product for the management of pain severe enough to long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults; and NUCYNTA IR (tapentadol), a product for the management of moderate to severe acute pain in adults. In addition, it is involved in the clinical development of Cebranopadol for the treatment of chronic nociceptive and neuropathic pain. It has a collaboration and license agreement with Ironwood Pharmaceuticals, Inc.; and a license agreement with Janssen Pharmaceuticals, Inc. based on its proprietary Acuform gastroretentive drug delivery technology. The company sells its products to wholesalers and retail pharmacies. The company was formerly known as Depomed Inc. and changed its name to Assertio Therapeutics, Inc. in August 2018 Assertio Therapeutics, Inc. was founded in 1995 and is headquartered in Lake Forest, Illinois.

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$76.49 million
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable

Receive ASRT News and Ratings via Email

Sign-up to receive the latest news and ratings for ASRT and its competitors with MarketBeat's FREE daily newsletter.


Depomed (NYSE:ASRT) Frequently Asked Questions

What is Depomed's stock symbol?

Depomed trades on the New York Stock Exchange (NYSE) under the ticker symbol "ASRT."

How were Depomed's earnings last quarter?

Depomed, Inc. (NYSE:ASRT) issued its quarterly earnings results on Wednesday, August, 7th. The company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by $0.01. The company earned $57.20 million during the quarter, compared to analysts' expectations of $58.49 million. View Depomed's Earnings History.

When is Depomed's next earnings date?

Depomed is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for Depomed.

What price target have analysts set for ASRT?

1 analysts have issued 1 year target prices for Depomed's shares. Their forecasts range from $3.00 to $3.00. On average, they expect Depomed's share price to reach $3.00 in the next year. This suggests a possible upside of 152.1% from the stock's current price. View Analyst Price Targets for Depomed.

What is the consensus analysts' recommendation for Depomed?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Depomed in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Depomed.

Has Depomed been receiving favorable news coverage?

Media coverage about ASRT stock has been trending neutral on Friday, according to InfoTrie Sentiment. The research firm identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Depomed earned a news impact score of 0.2 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Depomed.

Who are some of Depomed's key competitors?

What other stocks do shareholders of Depomed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Depomed investors own include InterDigital Wireless (IDCC), Bank of Hawaii (BOH), Stag Industrial (STAG), Fluent (FLNT), Baytex Energy (BTE), Kosmos Energy (KOS), Fuel Tech (FTEK), Extraction Oil & Gas (XOG), Crescent Point Energy (CPG) and SRC Energy (SRCI).

Who are Depomed's key executives?

Depomed's management team includes the folowing people:
  • Mr. Arthur Joseph Higgins, CEO, Pres & Director (Age 62)
  • Mr. Phillip B. Donenberg, CFO & Sr. VP (Age 57)
  • Mr. Sean P. McKercher, Sr. VP of Operations & Bus. (Age 61)
  • Dr. Stan Bukofzer, Sr. VP and Chief Medical & Scientific Officer (Age 62)
  • Mr. John B. Thomas, Sr. VP of IR & Corp. Communications (Age 54)

How do I buy shares of Depomed?

Shares of ASRT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Depomed's stock price today?

One share of ASRT stock can currently be purchased for approximately $1.19.

How big of a company is Depomed?

Depomed has a market capitalization of $77.14 million. View Additional Information About Depomed.

What is Depomed's official website?

The official website for Depomed is http://www.assertiotx.com/.


MarketBeat Community Rating for Depomed (NYSE ASRT)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  52 (Vote Outperform)
Underperform Votes:  55 (Vote Underperform)
Total Votes:  107
MarketBeat's community ratings are surveys of what our community members think about Depomed and other stocks. Vote "Outperform" if you believe ASRT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ASRT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel